Loading organizations...
Loading organizations...
Senda Biosciences is a technology company.
Sail Biomedicines is at the frontier of programmable medicines, harnessing evolution and AI to generate life-changing impact through innovative RNA technologies.
Senda Biosciences has raised $263.0M across 3 funding rounds.
Key people at Senda Biosciences.
Senda Biosciences was founded in 2023 by David Kolesky (Co-founder) and Ignacio Martinez (Co-Founder, Chairman of the Board) and John Casey (Co-Founder, Vice President, Head of Business Development).
Senda Biosciences has raised $263.0M in total across 3 funding rounds.
Senda Biosciences is a biotechnology company developing programmable medicines by harnessing nature's molecular codes, including mRNA and natural nanoparticles, to create targeted therapies for infectious diseases, oncology, autoimmune conditions, genetic diseases, and more.[1][2][4] Founded in 2016 and based in Cambridge, Massachusetts, the company raised $309.98M before merging with Laronde in October 2023 to form Sail Biomedicines, with its platform enabling SendRNA™ medicines that program cells for precise delivery and tunable effects like duration and immune response.[1][2] It serves patients with untreatable conditions by addressing challenges in drug targeting and cell programming, showing early preclinical momentum in COVID-19 vaccines and expansions into lung, stem cell, and in vivo CAR-T therapies.[1]
Senda Biosciences was founded in 2016 (with some sources noting 2017) by Flagship Pioneering, a venture studio known for pioneering biotech innovations, in Cambridge, MA.[1][2][4] The idea emerged from "intersystems" biology, aiming to program cells both within (e.g., mRNA) and to them (via natural nanoparticles from non-human cells in the human ecosystem), unlocking nature's evolutionary codes for medicine.[1][2][4] Early traction included a $98M Series B in June 2021 and $123M Series C in August 2022 from investors like Samsung Life Science Fund, Qatar Investment Authority, and Mayo Clinic, with preclinical successes in superior COVID-19 vaccine performance and programs in immuno-oncology and metabolic diseases; a pivotal merger with Laronde in 2023 advanced its RNA focus.[1][3][4]
Leadership includes CEO Guillaume Pfefer (ex-Kala Pharmaceuticals and GSK) and Head of Business Development John Casey, Jr. (ex-Inari and Kintai Therapeutics).[3]
Senda rides the mRNA and programmable medicine wave post-COVID, where RNA tech proved rapid vaccine development but faced limits in targeting and tunability; its nature-derived nanoparticles address delivery gaps, enabling in vivo programming for hard-to-reach cells.[1][2][3] Timing aligns with surging demand for precision therapies in oncology, autoimmunity, and genetics amid AI-driven drug discovery, positioning Senda to expand RNA's scope beyond vaccines into gene editing and protein therapies.[2][4] Market forces like investor interest (e.g., Qatar Investment Authority) and biotech M&A (e.g., its Sail merger) favor it, influencing the ecosystem by open-sourcing nature's codes to accelerate "intersystems" biology and reduce trial-and-error in untreatable diseases.[1][3][4]
Post-merger into Sail Biomedicines, Senda's platform will likely advance clinical COVID-19 vaccines and immune cell programming (e.g., in vivo CAR-T), expanding into lung, stem cells, and metabolic indications with partners.[1] Trends like AI-enhanced molecular atlases and nanoparticle evolution will amplify its edge, potentially transforming RNA from niche to ubiquitous for systemic diseases. Its influence may grow through Flagship's network, scaling programmable medicines to redefine biotech's speed and breadth—harnessing evolution's trillions of years to finally program the human body at will.[2][4]
Senda Biosciences was founded in 2023 by David Kolesky (Co-founder) and Ignacio Martinez (Co-Founder, Chairman of the Board) and John Casey (Co-Founder, Vice President, Head of Business Development).
Senda Biosciences has raised $263.0M in total across 3 funding rounds.
Senda Biosciences's investors include Flagship Pioneering, Cambridge Innovation Capital, Alexandria Venture Investments, Bluwave Capital, Longevity Vision Fund, Mayo Clinic, Partners Investment, Qatar Investment Authority, Samsung Life Science Fund, Stage 1 Ventures, State of Michigan Retirement System, Guillaume Pfefer.
Key people at Senda Biosciences.
Senda Biosciences has raised $263.0M across 3 funding rounds. Most recently, it raised $120.0M Series C in August 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 11, 2021 | Senda Biosciences | $55.0M Series B Extension | — | Alexandria Venture Investments, Guillaume Pfefer, Longevity Vision Fund, Mayo Clinic, Mint Venture Partners, Partners Investment, State of Michigan Retirement System, Terra Magnum Capital Partners |